ABSTRACT The intestinal gut health is one of the primary determinants of broiler growth and performance. Among the various enteric diseases, necrotic enteritis (NE) is an enterotoxemic disease caused by Clostridium perfringens, which can result in severe economic losses in poultry farming. Antibiotics like bacitracin methylene disalicylate (BMD) and avilamycin (AVL) are commonly used antibiotic growth promoters (AGP) in poultry feed to control necrotic enteritis in birds. Bacillus subtilis PB6 was reported to prevent necrotic enteritis and improve performance in birds. This paper investigated the influence of Bacillus subtilis PB6 in improving the performance of broiler birds in comparison with BMD and avilamycin. A 35 day trial was conducted with 240 day-old commercial broiler chicks (VenCobb 400), which were divided into four treatment groups, where each treatment group was composed of 6 replicates each containing 10 birds, for a total of 60 birds per treatment. The treatment groups included a negative control (no AGP), Bacillus subtilis PB6, BMD, and avilamycin. The parameters analyzed included body weight, feed conversion ratio (FCR), mortality, villus histomorphometry, and European efficiency factor (EEF). Bacillus subtilis PB6 significantly (P < 0.05) improved body weight and FCR (8 points) compared to the control. The group supplemented with B. subtilis PB6 or BMD had higher (P < 0.05) body weight compared to all other treatment groups. The supplementation of B. subtilis PB6 significantly improved the villus height (P < 0.05) compared to control and other AGP groups. The EEF was found to be the highest in the B. subtilis PB6 supplemented group at 35th day as compared to other treatment groups. The combined data from this study indicate that supplementation of B. subtilis PB6 improves overall performance of broilers compared to BMD and avilamycin, and can be used as potential AGP replacement in poultry farming.
INTRODUCTION
Poultry production has seen a dramatic change in the last four decades resulting in higher meat yield, improved feed conversion, and lower mortality rates (Shawkat et al., 2015) . The enormous improvements in growth rate and feed conversion ratio (FCR) in broiler production is demanding more care towards the bird's nutrition and health. The nutritional and health status of poultry are interlinked with gut health, which includes the immune system, gut microbial balance, and macro and micro-structural integrity of the gut (Kelly and Conway, 2001; Yegani and Korver, 2008) . The health of the gastrointestinal tract (GIT) affects digestion, absorption and metabolism of nutrients, disease resistance, and immune response (Kelly and C Conway, 2001; Yegani and Korver, 2008) . In commercial poultry production, approximately 60 to 70% of cost is factored towards feed (Khan et al., 2016) . The increasing cost of feed ingredients and immense desire to maximize nutrient utilization emphasizes the importance of maintaining good gut health.
Enteric diseases are one of the major problems in the poultry industry because of high economic losses due to decreased weight gain, increased mortality rates, lower FCR, greater medication costs, and increased risk of contamination of poultry products for human consumption (Timbermont et al., 2011) . Many conditions have been associated with gastrointestinal problems such as diarrhea, wet droppings, dysbacteriosis, intestinal colibacillosis, and malabsorption syndrome (Shawkat et al., 2015) . Enteric disorders are frequently associated with an overgrowth of Clostridium perfringens, resulting in necrotic enteritis (NE) . NE is the most common clostridial enteric disease in poultry, which typically occurs in broiler chickens (Cooper et al., 2013) . NE is characterized by necrosis and inflammation of the GIT with a significant decline in growth performance and, in clinical cases, a massive increase in flock mortality. The total cost of NE outbreaks globally is estimated to be over US$2 billion annually (Van der Sluis, 2000) .
Antibiotic growth promoters (AGP) have been included in poultry feeds worldwide at sub-therapeutic concentrations for their positive effects on weight gain, feed utilization, and mortality (Sims et al., 2004) . AGPs not only improve poultry growth and feed conversion efficiency, but also control enteric disease outbreak (Kim et al., 2011) . Although use of AGPs shows some positive effect on poultry production, there is increasing concerns on the use of AGPs resulting in the development of cross-resistance and multiple antibiotic resistances in pathogenic bacteria (Abudabos et al., 2013) . With a ban on in-feed antibiotics in European countries, the incidence of NE has increased on the broiler farms in these countries (Casewell et al., 2003; Hofacre et al., 2003) . This indicates the immense need and increasing demand for suitable antibiotic alternatives for the control and prevention of NE in broiler chicken.
Several reports have been published to demonstrate the use of probiotics, organic acids blends, dietary mannan oligosaccharides, and phytogenic feed additives as effective antibiotic alternatives (Hofacre et al., 2003; Sims et al., 2004; Awad et al., 2010; Kim et al., 2011) However, no product has been as effective as antibiotics in terms of controlling NE. This paper investigates the potential use of Bacillus subtilis PB6 (ATCC-PTA 6737) (PB6) as an AGP alternative in poultry production.
PB6 is a natural strain isolated from a healthy chicken gut that had been shown in vitro to produce antimicrobial substances, with broad activity against various strains of Escherichia coli, Campylobacter sp., and Clostridium sp. (Teo and Tan, 2005) . PB6 is known to secrete surfactins having anti-microbial activity (Teo and Tan, 2005) . These surfactins are amphipathic cyclic lipoheptapeptides belonging to the nonribosomal peptide family of natural products having exceptional emulsifying capabilities, as well as antibacterial, antiviral, and antitumor properties (Vollenbroich et al., 1997; Heerklotz and Seelig, 2001) .
The effect of PB6 on performance improvements in broilers is well documented Tan, 2006, 2007) . PB6 is also known to control and prevent NE in broilers challenged with C. perfringens (Abudabos et al., 2013; Sathishkumar et al., 2013) , and in broilers (Teo and Tan 2006) and laying hens (Sobczak and Koz lowski, 2015) . To further substantiate the use of PB6 as a potential AGP replacement in broiler production, this study compared the influence of PB6 in broiler performance and gut health in comparison to bacitracin methylene disalicylate (BMD) and avilamycin (AVL).
MATERIALS AND METHODS

Trial Location
The trial was conducted at a trial facility in the Department of Animal Nutrition, Faculty of Animal and Veterinary Sciences, West Bengal University of Animal and Fisheries sciences, Kolkata, West Bengal, India.
Birds and Treatment Groups
Two hundred and forty (240) day-old commercial broiler chicks (VenCobb 400), of either sex, were randomly divided into four (4) treatment groups, comprised of six replicates (6) each. Each replicate contained ten (10) birds for a total of sixty (60) birds per treatment. The trial duration was 35 days, and the birds were maintained on a deep litter system and fed with ad libitum corn-soybean based mash diet and water.
The trial contained four groups; one control group (negative control) and three treatments. The negative control group was fed with a corn-soybean based diet containing no active microbial or AGP. The other treatment groups contained either PB6, BMD, or AVL in the respective treatments (Table 1) . BMD was obtained from Zoetis Inc. (Mumbai, India) and AVL was obtained from Elanco (Bangalore, India). PB6 was obtained from Kemin Industries (Chennai, India). All the birds were vaccinated against Newcastle disease virus (NDV-B1, Lentogenic) on the third day, infectious bursal disease (IBD-Intermediate +) on the 12th day, and given a booster against NDV on the 28th day of the trial. All experimental protocols were approved by the Institutional Animal Ethics Committee in accordance with the procedures specified by the Committee for the Purpose of Control and Supervision of Experiments on Animals regarding animal care and handling. #Amount of each ingredient indicated in kg (formulation for 1 MT for each ration).
* Vitamin Premix -500 g of premix contains Vitamin A −12.5 MIU, Vitamin D3 -2.5 MIU, Vitamin E -12 g, Vitamin K -1.5 g, Vitamin B1 -1.5 g, Vitamin B2 -5 g, Vitamin B6 -2 g, Vitamin B12 -0.015 g, Niacin -15 g, Cal. D Pantothenate -10 g, Folic acid -0.5 g. * * Trace mineral contains manganese -54 g/kg, zinc − 52 g/kg, iron -20 g/kg, iodine -2 g/kg, copper − 2 g/kg, cobalt -1 g/kg * * * Enzymes: cellulase -8000 U/g, β-glucanase -700 U/g, protease -800 U/g, α-amylase -450 U/g, xylanase -2800 U/g, pectinase -300 U/g, lipase -10 U/g.
Feed Formulation and Preparation
The composition of the feed used in the trial is shown in Table 2 , and prepared in accordance with broiler nutritional requirements. The feed raw materials were weighed separately as per the feed formula and blended in the feed mixer (ribbon blender, 50 to 75 kg capacity) for 15 min. All feed additives (vitamins, minerals, amino acids, toxin binder, emulsifier, antibiotics, enzymes, antioxidants, liver tonic, and choline chloride) were first weighed on a laboratory weighing balance (Sartorius Secura 513-1S, Sartorius, Germany) to an accuracy of 0.001 g then combined as a premix before adding to the feed. The premix was added to the feed raw materials and mixed together for another 10 min. The final blended mash feed was packed in separate labeled high-density polyethylene bags with an inner liner. The nutritional composition of the feed ration is shown in Table 3 .
PB6 Recovery
Twenty five (25) gram samples of feed were added to 250 mL of 0.85% sterile saline and mixed for one minute. This was considered a 10 −1 dilution. The 10
dilution was kept in a water bath set at 80 • C ± 2 • C for 10 minutes. After heating in the water bath, serial dilutions were made up to 10 −7 . One mL from each dilution was then poured into a sterile petri-plate, in duplicate, and 20 mL of soyabean-casein digest agar (SCDA) with 0.6% yeast extract, containing metronidazole at 10 μg/mL, was added to the plates. The plates were rotated slowly clockwise and counterclockwise to ensure complete mixing. Plates were allowed to cool at room temperature, inverted, and placed in a biological incubator at 37
• C ± 2 • C under aerobic conditions for 24 hours.
Weekly Live Weight and Body Weight Gain
Each bird from each group was weighed individually on day one and at weekly intervals thereafter. Mean live body weight was computed at weekly intervals from the first week to the fifth week of the study. The difference in weight of the birds between the subsequent weeks was taken as the weekly body weight gain.
Feed Consumption
The feed consumption of each replicate was recorded daily by subtracting the weight of the residual feed from the total quantity of feed offered. After that, cumulative feed consumption was measured on a cumulative basis for each replicate.
FCR
The weekly FCR was calculated on a cumulative basis for each replicate. The FCR values of each treatment group were calculated at weekly intervals on the basis of weekly live weights and weekly feed consumption.
Mortality
Mortality was recorded in the different treatment groups and postmortem examination was conducted to diagnose the exact cause of death.
Villus Histomorphometry
The intestinal tissues from the duodenum and jejunum on day 35 of the trial were analyzed for histomorphometric studies. The formalin fixed tissues were sectioned at 3 to 5 micron thickness using a microtome machine and stained using hematoxylin and eosin stains. Stained tissue slides were observed on a computer assisted Microscope (Leica, Germany DM3000). Ten villi were randomly selected on each tissue slide and measured. The measurement for villi length was taken from the tip of the villus to the bottom. Crypt depth measurements were taken from base of the villus to the submucosa.
European Efficiency Factor (EEF)
At the end of the experimental period (35 days) the European efficiency factor (EEF) was calculated, based on the age of broilers at sacrifice, their average live weight, viability, and FCR. 
Statistical Analysis
The data obtained were subjected to analysis of variance (ANOVA) in a completely randomized design and treatment means were ranked using Duncan's multiple range tests using STATGRAHICS PLUS 5.0 (Statpoint Technologies, Inc USA). The differences at P < 0.05 were considered significant.
RESULTS
PB6 Recovery from Feed
Recovery of PB6 spores from the feed of the different treatment groups was analyzed and the results are shown in Table 4 . The recovery of PB6 spores was evident in all phases of the diet in the trial in the PB6 supplemented group. The other groups, namely negative control, BMD, and AVL were absent for PB6 spores. This result also showed that other treatment groups did not have any Bacillus spores in their respective feed. 
Body Weight of Birds
The body weight of birds throughout the trial period is shown in Table 5 . The group supplemented with PB6 or BMD had higher (P < 0.05) body weight compared to all other treatment groups. At the end of week 1, the negative control and the AVL supplemented groups had higher body weights, but as the weeks progressed, the groups supplemented with PB6 and BMD had higher body weights.
Feed Intake of Birds
The cumulative feed intake of birds through the trial period is shown in Table 6 . At week 1, the group supplemented with PB6 showed higher feed intake (P < 0.05) as compared to the other treatment groups. It was also observed that throughout the trial period that the PB6 treatment group had higher feed intake (P < 0.05) compared to the negative control and the treatment groups with AVL. By week 5, the treatment group supplemented with BMD showed higher feed consumption (P < 0.05) compared to other groups.
FCR
The FCR of the birds throughout the trial period is shown in Table 7 . The group supplemented with PB6 had the lowest FCR of all the treatments and was statistically (P < 0.05) better than the negative control group, resulting in 8 points of lower feed conversion. In addition, there were no significant differences between PB6, BMD, and the AVL treatment groups. Furthermore, supplementation of PB6 was numerically different than both the BMD and AVL treatments, resulting in 3 and 4 FCR points, respectively.
Mortality
No disease outbreak was observed during the trial period (35 days). Sporadic mortality was observed in different treatment groups (Table 8) , the majority of which occurred due to accidental injury. None of the feed additives were found to have any influence on mortality. Postmortem examination of dead birds revealed no pathognomonic lesions, only some physical injury varying from case to case. No statistical analysis was performed, as the mortality was considered for each treatment group and not considered for each replicate within each specific group. 
Villus Histomorphometry
The intestinal villus histomorphometry of the broiler birds is shown in Tables 9 and 10 . The villus height, crypt depth, and villus height to crypt depth ratio of the duodenum region are shown in Table 9 . Supplementation with PB6 significantly improved the villus height (P < 0.05) as compared to the negative control Groups that are significantly different from each other within column at P < 0.05 are indicated by different indices. All data are represented as mean ± standard error and the other AGP treatment groups. Supplementation with BMD and AVL decreased the villus height compared to the negative control. The crypt depth was significantly higher in the PB6 treatment group compared to the negative control. No significant difference in villus to crypt depth ratio was observed in the PB6 group compared to the negative control. However, significant differences were observed in villus height to crypt depth ratio between the PB6 and the BMD treatment groups.
The villus height, crypt depth, and villus height to crypt depth ratio of the jejunum region are shown in Table 10 . Supplementation with PB6 improved the villus height significantly (P < 0.05) compared to the other treatment groups. As observed in the duodenum region, supplementation with BMD and AVL decreased the villus height compared to the negative control. However, no statistical significance was observed. There was no significant difference observed in crypt depth in any of the treatment groups compared to the negative control. The villus height to crypt depth ratio in PB6 supplemented group was observed to be higher (P < 0.05), compared to other groups. Supplementation with BMD significantly lowered the villus height to crypt depth ratio compared to the negative control group and AVL also had a lower ratio compared to the negative however for AVL no significant difference was observed.
EEF
The EEF was found to be the highest in the PB6 treatment group at day 35 as compared to the other treatment groups (Table 11) . No statistical analysis was performed, as EEF was calculated for the entire flock in each treatment group and not considered as individual replicates.
DISCUSSION
There are multiple challenges associated with commercial poultry production including sky-rocketing increases in the price of feed ingredients, environmental stress, disease outbreaks, trade barriers, and a highly competitive business environment (Augustine and Shukla, 2015) . NE is one of the most common enteric diseases to occur in broiler birds. C. perfringens is the causative agent of NE and is a naturally occurring microbe usually found in low numbers in the hind gut. However, when there is a predisposing condition, such as coccidiosis, C. perfringens can migrate to the lower intestine where it produces enterotoxins. These toxins impair gut health and nutrient absorption which ultimately suppresses the production potential of birds (Craven et al., 1999) .
The use of antibiotic growth promoters in chicken can produce adverse effects such as an imbalance of normal microflora, a reduction in beneficial intestinal microbial populations, AGP residue in tissues even after long withdrawal periods, genotoxicity, and development of microbial resistance to specific antibiotics (Awad et al., 2010 and Kanduri et al., 2013) . Although certain antibiotics have been used to treat NE in poultry, strains of C. perfringens that were resistant to AGPs have been isolated from chickens and turkeys (Watkins et al., 1997) .
Several reports highlight the role of probiotic microorganisms as a good alternative to APGs. Probiotics are live microbial feed supplements, which beneficially affect the host animal by improving its intestinal microbial balance (Fuller, 1991 and Awad et al., 2009) . Studies have indicated that Bacillus subtilis can be used to increase and maintain beneficial bacteria in the intestine (Goldin, 1998) . Bacillus subtilis has been given the GRAS (generally regarded as safe) status and can be applied to both feed and food industries (Sharp et al., 1989) . Bacillus spp. can be administered orally as spores; the use of spores is more advantageous as they are heat resistant and tolerant of bile salts (Teo and Tan, 2006) .
PB6 is an active microbial that was isolated from a healthy chicken gut; the sporogenous form of this organism is known to possess commercially desired properties including heat resistant under pelleting conditions and tolerance to bile salts (Teo and Tan, 2006) . It is also known to produce of antimicrobial factor(s) that are capable of inhibiting Clostridium spp., Campylobacter spp., and Streptococcus spp. Tan, 2005 and Seah et al., 2002) . It was identified that certain surfactins as the major secondary metabolites responsible for this anticlostridial activity of PB6. There are also indications for the production of other antimicrobial actives by this strain including amicoumacins, (oxy)difficidin, (dihydro)bacillaene, and bacillomycin D (data not published). Several reports are published using PB6 as a feed additive where it was shown to improve poultry performance (Teo and Tan, 2006; Abudabos et al., 2013; Sathiskumar et al., 2013) . Though the beneficial effects of PB6 are well documented, it was essential to show that PB6 works as well as commercially available antibiotics if this product is to replace antibiotic use. This study proved the ability of PB6 to improve the performance of broiler birds equally as good as commonly used AGPs (BMD and AVL).
The influence of PB6 on immune response is already documented (Selvam et al., 2009) . Authors reported that oral administration of PB6 in a rat model significantly (P < 0.05) lowered the plasma levels of pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL -6, INF-gamma) and increased (P < 0.05) antiinflammatory cytokines (IL-10 and TGF-beta).
The PB6 recovery from the pre-starter, starter, and finisher feed indicated the possible usage of PB6 in animal feed (Table 4) . This is a key property of a probiotics to be actively available in bird's intestine.
The results from this study demonstrated that supplementation with PB6 provided equal or better broiler performance as compared to BMD and AVL. PB6 significantly improved body weight and FCR (8 points) compared to control and there were no statistically significance differences in FCR between PB6, BMD, and AVL, indicating performance improvements as good as APGs. Although not statistically significant, PB6 supplementation improved FCR by 3 and 4 points compared to BMD and AVL, respectively. This beneficial effect of PB6 could be attributed to various reasons such as proliferation of beneficial bacteria in the gut, reduction of pathogenic bacteria, improved gut health, increased villus histology, etc. Several papers report that use of PB6 reduces pathogens like C. perfringens (Teo and Tan, 2005; Sathiskumar et al., 2013) and E. coli (Teo and Tan, 2006) in the intestine, and prevents enteritis in poultry.
The effect of the different treatments on villus height showed a general trend that PB6 facilitated the growth of villi compared to the negative control, BMD, and AVL. It is also to be noted that both BMD and AVL had lower villus height compared to the negative control. This is in agreement with observations made by Samanta et al. (2010) , which showed that supplementation of BMD at 0.5 and 1.0 g/kg diet had lower villus height in duodenum, jejunum, and ileum compared to control. The villus in duodenum of PB6 supplemented groups showed an elongated, parallel, and wave-like appearance (Figure 1) . A wave-like disposition of the villi could facilitate a better contact between the nutrients and the absorptive surface of intestinal epithelium resulting in a better nutrient utilization (Yamauchi and Isshiki, 1991) . The ratio between the length of the villi and depth of the crypt is considered one of the most important parameters for intestinal health and recovery from NE. A high ratio indicates a long villus in which the epithelium is sufficiently maturated and functionally active, in combination with a shallow crypt with constant cell renewal. Birds suffering from chronic enteritis are in a constant mode of intestinal inflammation and intestinal recovery (Star et al., 2010) . This may lead to shortened villi and deeper crypts indicating faster tissue turnover, permitting renewal of the villus as needed in response to normal sloughing or inflammation from pathogens or their toxins. The effect on the birds would be poor nutrient absorption, increased secretion in the gastrointestinal tract, and lower performance (Xu et al., 2003) . The higher villus height coupled with higher villus to crypt depth ratio would be one of the possible reasons for the better body weight and FCR in the PB6 supplemented group.
EEF denotes the overall performance of a poultry flock. The formula takes into account data about flock mortality, live weight, and FCR. A higher EEF value represents higher profitability to the farmer. In this study, the group supplemented with PB6 had a higher EEF value as compared to the other treatment groups (Table 11 ). The higher EEF of the PB6 group was due to the higher body weight of the birds and the lower FCR.
From this study, it is evident that PB6 improves broiler growth and performance equally as well as the AGPs BMD and AVL, and can be used as an AGP replacement. The supplementation of PB6 not only improved broiler performance but also positively impacted villi histomorphometry, both strong indicator of good intestinal health.
